guanfacine has been researched along with Chronic Insomnia in 2 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Clonidine, melatonin, L-theanine, eszopiclone and guanfacine were well tolerated with mild to moderate adverse events; zolpidem was associated with neuropsychiatric adverse effects." | 2.55 | Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment. ( Anand, S; Besag, FMC; Chan, EW; Cortese, S; Tong, H; Wong, ICK, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anand, S | 1 |
| Tong, H | 1 |
| Besag, FMC | 1 |
| Chan, EW | 1 |
| Cortese, S | 1 |
| Wong, ICK | 1 |
| Rugino, TA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Observational Study Investigating the Experience of Patients Undergoing Active Insomnia Clinical Trials[NCT05978271] | 500 participants (Anticipated) | Observational | 2024-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for guanfacine and Chronic Insomnia
| Article | Year |
|---|---|
Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Eszopiclone; Glutamates; Guanfacine | 2017 |
1 trial available for guanfacine and Chronic Insomnia
| Article | Year |
|---|---|
Effect on Primary Sleep Disorders When Children With ADHD Are Administered Guanfacine Extended Release.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Chi | 2018 |